参考文献/References:
[1] Moak JP,Kaski JP. Hypertrophic cardiomyopathy in children[J]. Heart,2012,98(14):1044-1054.
[2] Colan SD,Lipshultz SE,Lowe AM,et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children[J]. Circulation,2007,115(6):773-781.
[3] Axelsson Raja A,Farhad H,Valente AM,et al. Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy[J]. Circulation,2018,138(8):782-792.
[4] Maron BJ,Desai MY,Nishimura RA,et al. Diagnosis and evaluation of hypertrophic?cardiomyopathy[J]. J Am Coll Cardiol,2022,79(4):372-389.
[5] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy[J]. Circulation,2020,142(25):e558-e563.
[6] Rupp S,Felimban M,Sch?nzer A,et al. Genetic basis of hypertrophic cardiomyopathy in children[J]. Clin Res Cardiol,2018,108(3):282-289.
[7] Ciampi Q,Olivotto I,Peteiro J,et al. Prognostic value of reduced heart rate reserve during exercise in hypertrophic cardiomyopathy[J]. J Clin Med,2021,10(7):1347.
[8] 蒋雨琦,束晶苇,俞宏林,等. 基于CMR电影序列的心肌收缩分数在射血分数保留的肥厚型心肌病中的价值[J]. 磁共振成像,2022,13(12):38-44.
[9] Norrish G,Ding T,Field E,et al. Relationship between maximal left ventricular wall thickness and sudden cardiac death in childhood onset hypertrophic cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2022,15(5):e010075.
[10] Monda E,Caiazza M,Cirillo C,et al. Patterns of left ventricular remodelling in children and young patients with hypertrophic cardiomyopathy[J]. J Clin Med,2024,13(13):3937.
[11] Xu J,Yang W,Zhao S,et al. State-of-the-art myocardial strain by CMR feature tracking:clinical applications and future perspectives[J]. Eur Radiol,2022,32(8):5424-5435.
[12] Yang L,Zhang L,Cao S,et al. Advanced myocardial characterization in hypertrophic cardiomyopathy:feasibility of CMR-based feature tracking strain analysis in a case-control study[J]. Eur Radiol,2020,30(11):6118-6128.
[13] Negri F,Muser D,Driussi M,et al. Prognostic role of global longitudinal strain by feature tracking in patients with hypertrophic cardiomyopathy:the STRAIN-HCM study[J]. Int J Cardiol,2021,345:61-67.
[14] Sunthankar S,Parra DA,George-Durrett K,et al. Tissue characterisation and myocardial mechanics using cardiac MRI in children with hypertrophic cardiomyopathy[J]. Cardiol Young,2019,29(12):1459-1467.
[15] 文苗,杨智,蒋小凤,等. 基于心脏磁共振组织追踪技术评估合并T2高信号的肥厚型心肌病患者左心室心肌损伤[J]. 放射学实践,2024,39(3):1313-1317.
[16] Bogarapu S,Puchalski MD,Everitt MD,et al. Novel cardiac magnetic resonance feature tracking (cmr-ft) analysis for detection of myocardial fibrosis in pediatric hypertrophic cardiomyopathy[J]. Pediatr Cardiol,2016,37(4):663-673.
[17] Song Y,Bi X,Chen L,et al. Reduced myocardial septal function assessed by cardiac magnetic resonance feature tracking in patients with hypertrophic obstructive cardiomyopathy:associated with histological myocardial fibrosis and ventricular arrhythmias[J]. Eur Heart J Cardiovasc Imaging,2022,23(8):1006-1015.
[18] Pu C,Fei J,Lv S,et al. Global circumferential strain by cardiac magnetic resonance tissue tracking associated with ventricular arrhythmias in hypertrophic cardiomyopathy patients[J]. Front Cardiovasc Med,2021,8:670361.
[19] Aguiar Rosa S,Rocha Lopes L,Fiarresga A,et al. Coronary microvascular dysfunction in hypertrophic cardiomyopathy:pathophysiology,assessment,and clinical impact[J]. Microcirculation,2020,28(1):e12656.
[20] 陈梓娴,张莉,南江,等. 心脏磁共振评估肥厚型心肌病微循环障碍的研究进展[J]. 中国医学影像学杂志,2023,31(2):180-184.
[21] Raphael CE,Mitchell F,Kanaganayagam GS,et al. Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy:the role of myocardial replacement fibrosis and the microcirculation[J]. J Cardiovasc Magn Reson,2021,23(1):26.
[22] Hughes RK,Camaioni C,Augusto JB,et al. Myocardial perfusion defects in hypertrophic cardiomyopathy mutation carriers[J]. J Am Heart Assoc,2021,10(15):e020227.
[23] 王家鑫,杨淑娟,马璇,等. 心脏磁共振在肥厚型心肌病危险分层中的研究[J]. 中华心血管病杂志,2023,51(6):619-625.
[24] Ong LT,Fan SWD. Prevalence and clinical significance of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy:a systematic review and meta-analysis[J]. Cardiol Young,2024,34(7):1456-1465.
[25] Chan RH,van der Wal L,Liberato G,et al. Myocardial scarring and sudden cardiac death in young patients with hypertrophic cardiomyopathy[J]. JAMA Cardiol,2024,9(11):1001-1008.
[26] Ali LA,Marrone C,Martins DS,et al. Prognostic factors in hypertrophic cardiomyopathy in children:an MRI based study[J]. Int J Cardiol,2022,364:141-147.
[27] Freitas P,Ferreira AM,Arteaga-Fernández E,et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death[J]. J Cardiovasc Magn Reson,2019,21(1):50.
[28] Rosu RO,Lupsor A,Necula A,et al. Anatomical-MRI correlations in adults and children with hypertrophic cardiomyopathy[J]. Diagnostics,2022,12(2):489.
[29] Wang S,Zhu C. Hypertrophic cardiomyopathy in children[J]. Asian Card Thorac Ann,2021,30(1):92-97.
[30] Elliott PM,Borger MA,Borggrefe M,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy[J]. Eur Heart J,2014,35(39):2733-2779.
[31] Lee S,Pahl E. Optimal imaging strategy for surveillance in children with hypertrophic cardiomyopathy[J]. Prog Pediatr Cardiol,2021,63:101432.
[32] Parekh K,Markl M,Deng J,et al. T1 mapping in children and young adults with hypertrophic cardiomyopathy[J]. Int J Cardiovasc Imaging,2016,33(1):109-117.
[33] Xu J,Zhuang B,Sirajuddin A,et al. MRI T1 mapping in hypertrophic cardiomyopathy:evaluation in patients without late gadolinium enhancement and hemodynamic obstruction[J]. Radiology,2020,294(2):275-286.
[34] Hinojar R,Varma N,Child N,et al. T1 mapping in discrimination of hypertrophic phenotypes:hypertensive heart disease and hypertrophic cardiomyopathy[J]. Circ Cardiovasc Imaging,2015,8(12):e003285.
[35] Gupta AN,Avery R,Soulat G,et al. Direct mitral regurgitation quantification in hypertrophic cardiomyopathy using 4D flow CMR jet tracking:evaluation in comparison to conventional CMR[J]. J Cardiovasc Magn Reson,2021,23(1):138.
[36] Iwata K,Sekine T,Matsuda J,et al. Measurement of turbulent kinetic energy in hypertrophic cardiomyopathy using triple-velocity encoding 4D flow MR imaging[J]. Magn Reson Med Sci,2024,23(1):39-48.
[37] van Ooij P,Allen BD,Contaldi C,et al. 4D flow MRI andT1-mapping:assessment of altered cardiac hemodynamics and extracellular volume fraction in hypertrophic cardiomyopathy[J]. J Magn Reson Imaging,2016,43(1):107-114.
[38] Fahmy AS,Neisius U,Chan RH,et al. Three-dimensional deep convolutional neural networks for automated myocardial scar quantification in hypertrophic cardiomyopathy:a multicenter multivendor study[J]. Radiology,2020,294(1):52-60.
[39] Shah R,Navidi Z,Sun J,et al. Interpretable machine learning for automated left ventricular scar quantification in hypertrophic cardiomyopathy patients[J]. PLOS Digital Health,2023,2(1):e0000159.
[40] Zhao K,Zhu Y,Chen X,et al. Machine learning in hypertrophic?cardiomyopathy[J]. JACC Cardiovasc Imaging,2024,17(8):880-893.
[41] Fahmy AS,Rowin EJ,Arafati A,et al. Radiomics and deep learning for myocardial scar screening in hypertrophic cardiomyopathy[J]. J Cardiovasc Magn Reson,2022,24(1):40.
[42] Chen WW,Kuo L,Lin YX,et al. A deep learning approach to classify Fabry cardiomyopathy from hypertrophic cardiomyopathy using cine imaging on cardiac magnetic resonance[J]. Int J Biomed Imaging,2024,2024:1-9.
[43] Huang S,Shi K,Zhang Y,et al. Texture analysis of T2-weighted cardiovascular magnetic resonance imaging to discriminate between cardiac amyloidosis and hypertrophic cardiomyopathy[J]. BMC Cardiovasc Disord,2022,22(1):235.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(7):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[3]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[4]吴洋.左室心肌致密化不全的心脏磁共振诊断[J].心血管病学进展,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
WU Yang.Diagnosis of Left Ventricular Non-compaction Cardiomyopathy With Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2019,(7):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
[5]徐源蔚 陈玉成.心脏磁共振在检测自身免疫性风湿疾病心脏受累中的应用进展[J].心血管病学进展,2019,(5):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
XU Yuanwei,CHEN Yucheng.Advances in the Application of Cardiac Magnetic Resonance in Detecting Cardiac Involvement in Autoimmune Rheumatic Disease[J].Advances in Cardiovascular Diseases,2019,(7):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
[6]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(7):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[7]冯泽豪 姜萌 卜军.心脏磁共振评价化疗所致心肌损伤的研究进展[J].心血管病学进展,2019,(5):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
FENG Zehao,JIANG Meng,PU Jun.Cardiovascular Magnetic Resonance for Detection of Myocardial Impairments Caused by Chemotherapy[J].Advances in Cardiovascular Diseases,2019,(7):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
[8]金荣杰 徐勇 邓珏琳 沈明志.应用心脏磁共振评估前列地尔对ST段抬高型心肌梗死患者心肌灌注的影响[J].心血管病学进展,2020,(10):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
JIN RongjieXU YongDENG JuelinSHEN Mingzhi.Effect of Alprostadil on Myocardial Perfusion of Patients with ST Segment Elevation Myocardial Infarction Directly Receiving Percutaneous Coronary Intervention Assessed with Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(7):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
[9]张宁 王嫱.心脏磁共振评估特发性炎症性肌病患者心脏受累的研究进展[J].心血管病学进展,2020,(11):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
ZHANG Ning,WANG Qiang.Advances in Evaluating Cardiac Involvement in Idiopathic Inflammatory Myopathy by Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(7):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
[10]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(7):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[11]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]